Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

AXL targeting overcomes human lung cancer cell resistance to NK and CTL-mediated cytotoxicity.

Terry S, Abdou A, Engelsen AST, Buart S, Dessen P, Corgnac S, Collares D, Meurice G, Gausdal G, Baud V, Saintigny P, Lorens JB, Thiery JP, Mami-Chouaib F, Chouaib S.

Cancer Immunol Res. 2019 Sep 5. pii: canimm.0903.2019. doi: 10.1158/2326-6066.CIR-18-0903. [Epub ahead of print]

PMID:
31488404
2.

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC.

Røsland GV, Dyrstad SE, Tusubira D, Helwa R, Tan TZ, Lotsberg ML, Pettersen IKN, Berg A, Kindt C, Hoel F, Jacobsen K, Arason AJ, Engelsen AST, Ditzel HJ, Lønning PE, Krakstad C, Thiery JP, Lorens JB, Knappskog S, Tronstad KJ.

Cancer Metab. 2019 Jun 1;7:6. doi: 10.1186/s40170-019-0197-8. eCollection 2019.

3.

A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells.

Bozickovic O, Skartveit L, Engelsen AST, Helland T, Jonsdottir K, Flågeng MH, Fenne IS, Janssen E, Lorens JB, Bjørkhaug L, Sagen JV, Mellgren G.

J Steroid Biochem Mol Biol. 2019 Jan;185:57-70. doi: 10.1016/j.jsbmb.2018.07.011. Epub 2018 Jul 23.

PMID:
30048685
4.

Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance.

Jokela TA, Engelsen AST, Rybicka A, Pelissier Vatter FA, Garbe JC, Miyano M, Tiron C, Ferariu D, Akslen LA, Stampfer MR, Lorens JB, LaBarge MA.

Front Cell Dev Biol. 2018 Apr 17;6:41. doi: 10.3389/fcell.2018.00041. eCollection 2018.

5.

Cancer Immunotherapy 2017 (Paris, France). Progress and challenges.

Chouaieb E, Terry S, Corgnac S, Engelsen AST.

Bull Cancer. 2018 May;105(5):537-541. doi: 10.1016/j.bulcan.2018.02.006. Epub 2018 Apr 12. No abstract available.

PMID:
29656785
6.

Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts.

Yttersian Sletta K, Tveitarås MK, Lu N, Engelsen AST, Reed RK, Garmann-Johnsen A, Stuhr L.

PLoS One. 2017 Aug 23;12(8):e0183254. doi: 10.1371/journal.pone.0183254. eCollection 2017.

7.

Adaptive mechanisms of resistance to anti-neoplastic agents.

Ferreira BI, Lie MK, Engelsen AST, Machado S, Link W, Lorens JB.

Medchemcomm. 2016 Oct 21;8(1):53-66. doi: 10.1039/c6md00394j. eCollection 2017 Jan 1. Review.

8.

Novel points of attack for targeted cancer therapy.

Røsland GV, Engelsen AS.

Basic Clin Pharmacol Toxicol. 2015 Jan;116(1):9-18. doi: 10.1111/bcpt.12313. Epub 2014 Oct 30. Review.

Supplemental Content

Loading ...
Support Center